drug · small molecule
nintedanib
Phase 3updated 6mo agoby Cloudbreak Therapeutics LLC🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 33 investigational indications.
indications
indications
Pulmonary Fibrosis
targets
Platelet-derived growth factor receptorVascular endothelial growth factor receptorFibroblast growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying nintedanib
- phase2Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
- —Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
- phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
- —Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
- phase1A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
- phase1Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
- —Real-life-persistence to Antifibrotic Treatments
- phase2Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
News(5)
- Bristol Myers dips on ‘confounding’ lung drug resultsOnly the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.biopharma_dive · 1mo ago
- Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitorEndeavor BioMedicines solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing to…fiercebiotech · 1mo ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 1mo ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 4mo ago
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.biopharma_dive · 6mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that